These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 8080734)
1. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734 [TBL] [Abstract][Full Text] [Related]
2. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy. Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876 [TBL] [Abstract][Full Text] [Related]
3. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733 [TBL] [Abstract][Full Text] [Related]
4. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. Jiang JT; Wu CP; Deng HF; Lu MY; Wu J; Zhang HY; Sun WH; Ji M World J Gastroenterol; 2004 Jun; 10(11):1675-7. PubMed ID: 15162550 [TBL] [Abstract][Full Text] [Related]
5. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Banfi G; Zerbi A; Pastori S; Parolini D; Di Carlo V; Bonini P Clin Chem; 1993 Mar; 39(3):420-3. PubMed ID: 8448851 [TBL] [Abstract][Full Text] [Related]
6. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294 [TBL] [Abstract][Full Text] [Related]
7. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Gui JC; Yan WL; Liu XD Clin Exp Med; 2014 May; 14(2):225-33. PubMed ID: 23456571 [TBL] [Abstract][Full Text] [Related]
8. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Nilsson O; Johansson C; Glimelius B; Persson B; Nørgaard-Pedersen B; Andrén-Sandberg A; Lindholm L Br J Cancer; 1992 Feb; 65(2):215-21. PubMed ID: 1739620 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer]. Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811 [TBL] [Abstract][Full Text] [Related]
10. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Furuya N; Kawa S; Hasebe O; Tokoo M; Mukawa K; Maejima S; Oguchi H Br J Cancer; 1996 Feb; 73(3):372-6. PubMed ID: 8562344 [TBL] [Abstract][Full Text] [Related]
11. Application values of detection of serum CA199, CA242 and CA50 in the diagnosis of pancreatic cancer. Lei XF; Jia SZ; Ye J; Qiao YL; Zhao GM; Li XH; Chang H J Biol Regul Homeost Agents; 2017; 31(2):383-388. PubMed ID: 28685541 [TBL] [Abstract][Full Text] [Related]
12. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases. Yang XQ; Chen C; Peng CW; Liu SP; Li Y Med Oncol; 2012 Jun; 29(2):1030-6. PubMed ID: 21553105 [TBL] [Abstract][Full Text] [Related]
13. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer. Banfi G; Bravi S; Ardemagni A; Zerbi A Int J Biol Markers; 1996; 11(2):77-81. PubMed ID: 8776607 [TBL] [Abstract][Full Text] [Related]
14. Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer. Liu F; Du F; Chen X World J Surg Oncol; 2014 Nov; 12():333. PubMed ID: 25381564 [TBL] [Abstract][Full Text] [Related]
15. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219 [TBL] [Abstract][Full Text] [Related]
16. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers]. Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):741-4. PubMed ID: 16255879 [TBL] [Abstract][Full Text] [Related]
17. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients. Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815 [TBL] [Abstract][Full Text] [Related]
18. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Jiang XT; Tao HQ; Zou SC Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798 [TBL] [Abstract][Full Text] [Related]
20. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients. Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]